Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
(NQ: )
N/A   UNCHANGED
Last Price  /  Updated:   /  Add to My Watchlist      
View: Quote News
All news about
 
< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Alkermes (ALKS) Opens Dublin HQ, Enters Large Manufacturing Agreement
September 19, 2011
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=6794133 for the full story. Read More
from StreetInsider.com News Articles
Alkermes plc Launches Corporate Operations in Ireland
September 19, 2011
from Business Wire News Releases
Alkermes (ALKS), Elan Complete $1B Cash and Stock Merger
September 16, 2011
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=6792512 for the full story. Read More
from StreetInsider.com News Articles
Alkermes plc and Elan Corporation plc Announce Completion of Merger Between Alkermes, Inc. and Elan Drug Technologies
September 16, 2011
from Business Wire News Releases
Data Announced On Bydureon
September 13, 2011
Alkermes, Inc. (NASDAQ:ALKS), Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) and Eli Lilly and Company (NYSE:LLY) recently announced new analyses of data from the DURATION 3 and DURATION 4 trials which... Read More
category AMLN , ALKS , External Research , and 7 more.
from DailyMarkets.com
Lilly, Amylin, Merck Diabetes Drug Risks Highlighted
September 13, 2011
Hope for the diabetes drug Bydureon -- developed by Amylin Pharmaceuticals (AMLN) Eli Lilly (LLY) and Alkermes (ALKS) -- has ebbed and flowed over the past year. Last October the drug a once-weekly... Read More
from Minyanville Headlines
Amylin (AMLN), Alkermes (ALKS), Lilly (LLY) Report Strong Data from BYDUREON DURATION-3 and -4
September 12, 2011
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=6776786 for the full story. Read More
from StreetInsider.com News Articles
Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors: Results Presented at EASD 2011
September 12, 2011
from Business Wire News Releases
Analyses Find Type 2 Diabetes Patients Treated with BYDUREON™ Experienced Reduction in Cardiovascular Risk Factors: Results Presented at EASD 2011
September 12, 2011
Composite Endpoint Included Body Weight, Blood Pressure and Lipid Levels Read More
from PR Newswire
Alkermes Announces Shareholder Vote in Favor of Merger with Elan Drug Technologies
September 08, 2011
from Business Wire News Releases
Alkermes’ Corporate Presentation to be Webcast at Two Upcoming Conferences
September 07, 2011
from Business Wire News Releases
(ALKS) Alkermes Analyst Maintains Neutral Rating on Shares
September 01, 2011
We are maintaining our Neutral recommendation on Alkermes, Inc. (ALKS). Alkermes is a drug delivery... Visit StockBlogHub to view complete post. Read More
category Glaxosmithkline plc , ALKS , Johnson & Johnson , and 15 more.
from Stock Blog Hub
Equity Research on Alkermes Inc. and Hospira Inc. - Drug Delivery Sector's Relationship With the FDA
September 01, 2011
from Marketwired News Releases
Alkermes’ Corporate Presentation to Be Webcast at Baird’s 2011 Health Care Conference
August 31, 2011
from Business Wire News Releases
Risk Reward Balances Alkermes
August 31, 2011
We are maintaining our Neutral recommendation on Alkermes, Inc. (NASDAQ:ALKS). Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop... Read More
category AMLN , ALKS , External Research , and 6 more.
from DailyMarkets.com
Caris & Co. Upgrades Alkermes (ALKS) to Buy
August 30, 2011
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=6750477 for the full story. Read More
from StreetInsider.com News Articles
Factors Moving Markets, Worldwide View - Equity Research on Alkermes, Inc. and Forest Laboratories, Inc.
August 25, 2011
from Marketwired News Releases
Alkermes (ALKS): Upgraded by UBS
August 24, 2011
from Comtex SmarTrend® News Briefs
Wall Street Analyst Actions 08-23-11
August 23, 2011
category Analyst/Actions
from Wall Street Greek
UPDATE - UBS Upgraded Alkermes (ALKS) to Buy; Compelling Story at Current Levels
August 23, 2011
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=6737211 for the full story. Read More
from StreetInsider.com News Articles
Up/Downgrades (AET, ALKS, CNP, CYN, COH, HWAY, JNPR, LNN, NRG, PWRD, SAFM, HRL, LNCR, PEG, STP)
August 23, 2011
New York, August 23rd (TradersHuddle.com) – Following are some of the top upgrades and downgrades before the market open. Upgrades Aetna (<a href="http://www.trad. Read More -- Read More
from TradersHuddle.com
UBS Upgrades Alkermes (ALKS) to Buy
August 23, 2011
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=6736157 for the full story. Read More
from StreetInsider.com News Articles
Earnings Flashback: Since Reporting Quarterly Results 18 Days Ago Alkermes Is Down 12.66% (ALKS)
August 21, 2011
from Comtex SmarTrend® News Briefs
Biotech analysts see plunge as buying opportunity
August 12, 2011
While most investors fled for safer havens this week, biotech analysts were advising clients to take advantage of discounted stock prices. Read More
category ITMN , Biotechnology , Retail , and 20 more.
from MarketWatch
Amylin (AMLN), Lilly (LLY), Alkermes (ALKS) Receive PDUFA Date for BYDUREON
August 10, 2011
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=6704976 for the full story. Read More
from StreetInsider.com News Articles
BYDUREON™ FDA Action Date Set for January 28, 2012
August 10, 2011
from Business Wire News Releases
BYDUREON™ FDA ACTION DATE SET FOR JANUARY 28, 2012
August 10, 2011
from PR Newswire
The Zacks Analyst Blog Highlights: Alkermes, Johnson & Johnson, Amylin Pharmaceuticals, Eli Lilly and Company and Elan Corporation
August 04, 2011
from PR Newswire
The Secret to Alerkmes' Success
August 02, 2011
Alerkmes' CEO Richard Pops tells Cramer why the company is successful, and where it is going. Read More
category Health Care , Savient Pharmaceuticals Inc , Investing/Stock Market/Stock Picks , and 5 more.
from CNBC.com News
Alkermes, Inc. (ALKS) Posts Wider than Expected Q1 Loss
August 01, 2011
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=6673928 for the full story. Read More
from StreetInsider.com News Articles
< Previous 1 2 3 4 5 6 7 8 9
...
26 27 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here